The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei .

Autor: Nelson M; Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK., Barnes KB; Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK., Davies CH; Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK., Cote CK; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA., Meinig JM; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA., Biryukov SS; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA., Dyer DN; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA., Frick O; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA., Heine H; Institute for Therapeutic Innovation, University of Florida, Orlando, FL 32827, USA., Pfefferle DA; Battelle Memorial Institute, Columbus, OH 43201, USA., Horstman-Smith A; Parsons Corporation, Centerville, VA 20120, USA., Barbaras J; Defense Threat Reduction Agency, Fort Belvoir, VA 22060, USA., Harding SV; Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK.; School of Respiratory Sciences, University of Leicester, Leicester LE1 7RH, UK.
Jazyk: angličtina
Zdroj: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2023 Mar 03; Vol. 12 (3). Date of Electronic Publication: 2023 Mar 03.
DOI: 10.3390/antibiotics12030506
Abstrakt: Burkholderia pseudomallei , the causative agent of the disease melioidosis, has been isolated from the environment in 45 countries. The treatment of melioidosis is complex, requiring lengthy antibiotic regimens, which can result in the relapse of the disease following treatment cessation. It is important that novel therapies to treat infections with B. pseudomallei be assessed in appropriate animal models, and discussions regarding the different protocols used between laboratories are critical. A 'deep dive' was held in October 2020 focusing on the use of the BALB/c mouse model and the inhalational route of infection to evaluate new antibiotic therapies.
Databáze: MEDLINE